Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 16/20 | 0.37 |
| ▸ | LIPC | P11150 | 7/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.35 |
| ▸ | PI4KA | P42356 | 3/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.35 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14729078 | 0.85 | GPR119 (0.41) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL14729087 | 0.82 | GPR119 (0.43) | LIPGLIPC | |
| SCHEMBL14729084 | 0.77 | GPR119 (0.53) | — | |
| SCHEMBL14729089 | 0.76 | GPR119 (0.42) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL14729086 | 0.74 | GPR119 (0.54) | — | |
| SCHEMBL14728914 | 0.69 | GPR119 (0.46) | — | |
| SCHEMBL14728928 | 0.69 | GPR119 (0.55) | — | |
| SCHEMBL14729090 | 0.68 | GPR119 (0.53) | — | |
| SCHEMBL14729088 | 0.68 | GPR119 (0.53) | — | |
| SCHEMBL10067702 | 0.67 | GPR119 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2566860-B1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | GPR119, GPR139, GPR4 | LIPG 1497/4885LIPC 1982/4885PIK3CD 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.